Clinical Trial Update: A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial comparing three doses of oral LEO 22811 to placebo in psoriasis vulgaris; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• LEO 22811

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2018-10-03